HIV and hepatitis C co-infection

被引：17

作者：

Jones, R ^{[1
]}

Dunning, J ^{[1
]}

Nelson, M ^{[1
]}

机构：

[1] Chelsea & Westminster Hosp, Dept HIV & GU Med, London SW10 9NH, England

来源：

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 2005年 / 59卷 / 09期

关键词：

HIV; hepatitis C; co-infection;

D O I：

10.1111/j.1742-1241.2005.00596.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

HIV/HCV co-infection is emerging as a major cause of morbidity and mortality in the 21st century. This editorial reviews the prevalence of co-infection, the factors involved in acquisition of HCV, and the influence of co-infection on disease progression. We examine the results of the major co-infection trials including APRICOT, ACTG 5071 and RIBAVIC. These trials, in association with emerging evidence for future therapies currently undergoing investigation, have led to increased hope of treatment success in co-infected individuals.

引用

页码：1082 / 1087

页数：6

共 46 条

[1] Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients [J].

Benhamou, Y ;

Bochet, M ;

Di Martino, V ;

Charlotte, F ;

Azria, F ;

Coutellier, A ;

Vidaud, M ;

Bricaire, F ;

Opolon, P ;

Katlama, C ;

Poynard, T .

HEPATOLOGY, 1999, 30 (04) :1054-1058

[2] Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection [J].

Bica, I ;

McGovern, B ;

Dhar, R ;

Stone, D ;

McGowan, K ;

Scheib, R ;

Snydman, DR .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :492-497

[3]

Bodsworth NJ, 1996, GENITOURIN MED, V72, P118

[4]

BROWNE R, 2003, 9 ANN M BRIT HIV ASS

[5] Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997 [J].

Cacoub, P ;

Geffray, L ;

Rosenthal, E ;

Perronne, C ;

Veyssier, P ;

Raguin, G .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (08) :1207-1214

[6] Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial [J].

Carrat, F ;

Bani-Sadr, F ;

Pol, S ;

Rosenthal, E ;

Lunel-Fabiani, F ;

Benzekri, A ;

Morand, P ;

Goujard, C ;

Pialoux, G ;

Piroth, L ;

Salmon-Céron, D ;

Degott, C ;

Cacoub, P ;

Perronne, C .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23) :2839-2848

[7]

CHAIX M, 2004, 55 ANN M AM SOC STUD

[8] Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons [J].

Chung, RT ;

Andersen, J ;

Volberding, P ;

Robbins, GK ;

Liu, T ;

Sherman, KE ;

Peters, MG ;

Koziel, MJ ;

Bhan, AK ;

Alston, B ;

Colquhoun, D ;

Nevin, T ;

Harb, G ;

van der Horst, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :451-459

[9] Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects [J].

Chung, RT ;

Evans, SR ;

Yang, YJ ;

Theodore, D ;

Valdez, H ;

Clark, R ;

Shikuma, C ;

Nevin, T ;

Sherman, KE .

AIDS, 2002, 16 (14) :1915-1923

[10]

COWLING B, 2004, 15 INT AIDS C BANGK

← 1 2 3 4 5 →